This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HSIC vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
Nevro's (NVRO) Senza System Approved by FDA for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) 10 kHz SCS treatment, which has received the FDA nod for treating patients with PDN, is expected to provide sustained pain relief as well as improve health-related quality of life.
Boston Scientific (BSX) Watchman FLX Sales to Aid Q2 Earnings
by Zacks Equity Research
Strong procedure recovery and market share gains across many of the businesses and regions are expected to have boosted Boston Scientific's (BSX) Q2 sales.
Nevro (NVRO) Reports Impressive Preliminary Q2 Revenues
by Zacks Equity Research
Improvement in Nevro's (NVRO) second-quarter revenues is likely to have resulted from a solid product portfolio.
Masimo (MASI) Boosts Its Product Suite With Latest Release
by Zacks Equity Research
Masimo's (MASI) latest offering is expected to improve patient care due to its re-engineered integration design.
Cerner (CERN) Extends Partnership to Accelerate Digital Health
by Zacks Equity Research
Cerner (CERN) expands its partnership with Baystate Health by launching a digital health platform to boost consumer-focused care.
Cardinal Health (CAH) Introduces 2 New Digital Solutions
by Zacks Equity Research
Cardinal Health (CAH) launches NavixRx Compliance Packaging and E-Commerce Storefront to allow independent pharmacists to expand services and support medication adherence.
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
Base Test Rebound to Drive Quest Diagnostics (DGX) Q2 Earnings
by Zacks Equity Research
Quest Diagnostics' (DGX) second-quarter performance within its non-COVID base business might have registered significant sales rebound.
Why Henry Schein (HSIC) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Lower COVID-19 Testing Demand to Drag Abbott (ABT) Q2 Earnings
by Zacks Equity Research
Apart from COVIG-19 test related hiccups, Abbott (ABT) is likely to have suffered from significant sales decline within its pediatric nutrition business in Q2.
3 Stocks to Tap the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Is Henry Schein (HSIC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Stryker (SYK) Unveils Tornier Shoulder Arthroplasty Portfolio
by Zacks Equity Research
Stryker (SYK) introduces new Tornier shoulder arthroplasty portfolio enabling the company to strengthen its position in the shoulder market.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.
What Makes Align Technology (ALGN) a Solid Choice Right Now?
by Zacks Equity Research
Strong performance and latest innovations in the Invisalign and iTero family are driving the top line for Align Technology (ALGN).
Dental Space Gains Momentum in 2021: 4 Stocks to Invest in
by Debanjana Dey
Dental stocks like Henry Schein (HSIC), Align Technology (ALGN), Straumann Holding (SAUHF) and DENTSPLY SIRONA (XRAY) are expected to continue their run over the next few months.
Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market
by Riya Anand
Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.
HSIC vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
Top Ranked Growth Stocks to Buy for July 1st
by Zacks Equity Research
VALE, HCCI, X, and HSIC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 1, 2021
3 Reasons to Add AMN Healthcare (AMN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about AMN Healthcare (AMN) due to its broad array of services and strength in staffing service.
3 Best MedTech Growth Stocks to Bet On in 2021 Amid Pandemic
by Trina Mukherjee
Grab these three top stocks, EYE, WST and HSIC, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
Top Ranked Growth Stocks to Buy for June 29th
by Zacks Equity Research
HCCI, X, TGT, and HSIC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 29, 2021
Walgreens (WBA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Faster adoption of digital health and improved business environment are expected to have contributed to Walgreens' (WBA) third-quarter performance.